Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Subhash, Vinod Vijay ^a   Yeo, Mei Shi ^b   Tan, Woei Loon ^b   Yong, Wei Peng ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CHIMERIC ANTIGEN RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; DURVALUMAB; IMMUNOMODULATING AGENT; IPILIMUMAB; MPDL 3280A; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; T LYMPHOCYTE ANTIGEN; TICILIMUMAB; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOSURVEILLANCE; INNATE IMMUNITY; MULTICENTER STUDY (TOPIC); NATURAL KILLER CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH CANCER; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; CLINICAL TRIAL (TOPIC); IMMUNITY; IMMUNOLOGICAL MEMORY; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; STOMACH NEOPLASMS;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNE SYSTEM PHENOMENA; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; MONITORING, IMMUNOLOGIC; STOMACH NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84947104541     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/308574     Document Type: Review

References (112)

1. H.-R. Shin, M. C. Carlos, and C. Varghese, "Cancer control in the Asia Pacific region: current status and concerns," Japanese Journal of Clinical Oncology, vol. 42, no. 10, Article ID hys077, pp. 867-881, 2012.
2. A. Biondi, R. Persiani, F. Cananzi et al., "R0 resection in the treatment of gastric cancer: room for improvement," World Journal of Gastroenterology, vol. 16, no. 27, pp. 3358-3370, 2010.
3. D. Cunningham, N. Starling, S. Rao et al., "Capecitabine and oxaliplatin for advanced esophagogastric cancer," The New England Journal of Medicine, vol. 358, no. 1, pp. 36-46, 2008.
4. J. S. Park, J. Y. Lim, S. K. Park et al., "Prognostic factors of second and third line chemotherapy using 5-FU with platinum, irinotecan, and taxane for advanced gastric cancer," Cancer Research and Treatment, vol. 43, no. 4, pp. 236-243, 2011.
5. Y.-J. Bang, E. Van Cutsem, A. Feyereislova et al., "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial," The Lancet, vol. 376, no. 9742, pp. 687-697, 2010.
6. Y. Ishimine, A. Goto, Y. Watanabe et al., "Loss of HER2 positivity after trastuzumab in HER2-positive gastric cancer: is change in HER2 status significantly frequent?" Case Reports in Gastrointestinal Medicine, vol. 2015, Article ID 132030, 6 pages, 2015.
7. C. S. Fuchs, J. Tomasek, C. J. Yong et al., "Ramucirumab monotherapy for previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial," The Lancet, vol. 383, no. 9911, pp. 31-39, 2014.
8. H. Wilke, K. Muro, E. Van Cutsem et al., "Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial," The Lancet Oncology, vol. 15, no. 11, pp. 1224-1235, 2014.
9. T. Waddell, I. Chau, D. Cunningham et al., "Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial," The Lancet Oncology, vol. 14, no. 6, pp. 481-489, 2013.
10. F. Lordick, Y.-K. Kang, H.-C. Chung et al., "Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial," The Lancet Oncology, vol. 14, no. 6, pp. 490-499, 2013.
11. M. Mayr, K. Becker, N. Schulte et al., "Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma," BMC Cancer, vol. 12, article 587, 2012.
12. P. B. Chapman, S. P. D'Angelo, and J. D. Wolchok, "Rapid eradication of a bulky melanoma mass with one dose of immunotherapy,"TheNewEngland Journal ofMedicine, vol. 372, no. 21, pp. 2073-2074, 2015.
13. S. Matsueda and D. Y. Graham, "Immunotherapy in gastric cancer," World Journal of Gastroenterology, vol. 20, no. 7, pp. 1657-1666, 2014.
14. L. A. Emens and G. Middleton, "The interplay of immunotherapy and chemotherapy: harnessing potential synergies," Cancer Immunology Research, vol. 3, no. 5, pp. 436-443, 2015.
15. D.M. Pardoll, "The blockade of immune checkpoints in cancer immunotherapy," Nature Reviews Cancer, vol. 12, no. 4, pp. 252-264, 2012.
16. A. Cimino-Mathews, J. B. Foote, and L. A. Emens, "Immune targeting in breast cancer," Oncology, vol. 29, pp. 375-385, 2015.
17. R. D. Schreiber, L. J. Old, and M. J. Smyth, "Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion," Science, vol. 331, no. 6024, pp. 1565-1570, 2011.
18. D.Mittal, M. M. Gubin, R.D. Schreiber, andM. J. Smyth, "New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape," Current Opinion in Immunology, vol. 27, no. 1, pp. 16-25, 2014.
19. O. S. Qureshi, Y. Zheng, K.Nakamura et al., "Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4," Science, vol. 332, no. 6029, pp. 600-603, 2011.
20. A. Pedoeem, I. Azoulay-Alfaguter, M. Strazza, G. J. Silverman, and A. Mor, "Programmed death-1 pathway in cancer and autoimmunity," Clinical Immunology, vol. 153, no. 1, pp. 145-152, 2014.
21. M. Sznol, "Blockade of the B7-H1/PD-1 pathway as a basis for combination anticancer therapy," Cancer Journal, vol. 20, no. 4, pp. 290-295, 2014.
22. C. E. Weber and P. C. Kuo, "The tumor microenvironment," Surgical Oncology, vol. 21, no. 3, pp. 172-177, 2012.
23. T. Ishimoto, H. Sawayama, H. Sugihara, and H. Baba, "Interaction between gastric cancer stem cells and the tumor microenvironment," Journal of Gastroenterology, vol. 49, no. 7, pp. 1111-1120, 2014.
24. Z. N. Oltvai and A.-L. Barabási, "Systems biology. Life's complexity pyramid," Science, vol. 298, no. 5594, pp. 763-764, 2002.
25. T. Blankenstein, P. G. Coulie, E. Gilboa, and E. M. Jaffee, "The determinants of tumour immunogenicity," Nature Reviews Cancer, vol. 12, no. 4, pp. 307-313, 2012.
26. A. Amedei, C. Della Bella, E. Silvestri, D. Prisco, and M. M. D'Elios, "T cells in gastric cancer: friends or foes," Clinical and Developmental Immunology, vol. 2012, Article ID 690571, 10 pages, 2012.
27. S. Ishigami, S. Natsugoe, K. Tokuda et al., "Tumor-associated macrophage (TAM) infiltration in gastric cancer," Anticancer Research, vol. 23, no. 5, pp. 4079-4083, 2003.
28. J. B. Mitchem, D. J. Brennan, B. L. Knolhoff et al., "Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses," Cancer Research, vol. 73, no. 3, pp. 1128-1141, 2013.
29. A. Amedei,M. Benagiano, C. della Bella, E. Niccolai, andM.M. D'Elios, "Novel immunotherapeutic strategies of gastric cancer treatment," Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 437348, 17 pages, 2011.
30. K. Palucka and J. Banchereau, "Cancer immunotherapy via dendritic cells," Nature Reviews Cancer, vol. 12, no. 4, pp. 265-277, 2012.
31. E. Gilboa, "DC-based cancer vaccines," The Journal of Clinical Investigation, vol. 117, no. 5, pp. 1195-1203, 2007.
32. S. Ishigami, S. Natsugoe, K. Tokuda et al., "Prognostic value of intratumoral natural killer cells in gastric carcinoma," Cancer, vol. 88, no. 3, pp. 577-583, 2000.
33. E.Niccolai, A. Taddei,D. Prisco, and A. Amedei, "Gastric cancer and the epoch of immunotherapy approaches," World Journal of Gastroenterology, vol. 21, no. 19, pp. 5778-5793, 2015.
34. U. Petrausch, C. H. Poehlein, S. M. Jensen et al., "Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects," CurrentMolecular Medicine, vol. 9, no. 6, pp. 673-682, 2009.
35. V. Zorzetto, G. Maddalo, D. Basso, and F. Farinati, "Immunotherapy for gastric premalignant lesions and cancer," Immunotherapy, vol. 4, no. 6, pp. 587-599, 2012.
36. K. Kono, A. Takahashi, F. Ichihara et al., "Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial," Clinical Cancer Research, vol. 8, no. 6, pp. 1767-1771, 2002.
37. N. Sadanaga, H. Nagashima, K. Mashino et al., "Dendritic cell vaccination withMAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas," Clinical Cancer Research, vol. 7, no. 8, pp. 2277-2284, 2001.
38. T.W. Kim, C.-F. Hung, D. Boyd et al., "Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies," Journal of Immunology, vol. 171, no. 6, pp. 2970-2976, 2003.
39. T.H.Kang, J. H. Lee, K. H. Noh et al., "Enhancing dendritic cell vaccine potency by combining a BAK/BAX siRNA-mediated antiapoptotic strategy to prolong dendritic cell life with an intracellular strategy to target antigen to lysosomal compartments," International Journal of Cancer, vol. 120, no. 8, pp. 1696-1703, 2007.
40. S.-B. He, K. Sun, L. Wang, D.-C. Li, and Y.-Y. Zhang, "GMCSF gene-modified dendritic cell vaccine enhances antitumor immunity in vitro," Zhonghua Zhong Liu Za Zhi, vol. 32, no. 6, pp. 410-414, 2010.
41. J. H. Kim, T. H. Kang, K. H. Noh et al., "Enhancement of DC vaccine potency by activating the PI3K/AKT pathway with a small interfering RNA targeting PTEN," Immunology Letters, vol. 134, no. 1, pp. 47-54, 2010.
42. J. H. Kim, T. H. Kang, K. H. Noh et al., "Blocking the immunosuppressive axis with small interfering RNA targeting interleukin (IL)-10 receptor enhances dendritic cell-based vaccine potency," Clinical and Experimental Immunology, vol. 165, no. 2, pp. 180-189, 2011.
43. J. A. Ajani, J. R. Hecht, L. Ho et al., "An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study," Cancer, vol. 106, no. 9, pp. 1908-1916, 2006.
44. O. E. Rahma and S. N. Khleif, "Therapeutic vaccines for gastrointestinal cancers," Gastroenterology and Hepatology, vol. 7, no. 8, pp. 517-564, 2011.
45. Y. Sato,H. Shomura, Y.Maeda et al., "Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide," Cancer Science, vol. 94, no. 9, pp. 802-808, 2003.
46. J. Yang, Z.-H. Li, J.-J. Zhou et al., "Preparation and antitumor effects of nanovaccines with MAGE-3 peptides in transplanted gastric cancer in mice," Chinese Journal of Cancer, vol. 29, no. 4, pp. 359-364, 2010.
47. T. Masuzawa, Y. Fujiwara, K. Okada et al., "Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer," International Journal ofOncology, vol. 41, no. 4, pp. 1297-1304, 2012.
48. S. Kim, K. Iizuka, H. L. Aguila, I. L. Weissman, and W. M. Yokoyama, "In vivo natural killer cell activities revealed by natural killer cell-deficient mice," Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 6, pp. 2731-2736, 2000.
49. M.Cheng,Y.Chen,W. Xiao,R.Sun, andZ. Tian, "NKcell-based immunotherapy formalignant diseases," Cellular andMolecular Immunology, vol. 10, no. 3, pp. 230-252, 2013.
50. C. J.Voskens,R.Watanabe, S. Rollins, D. Campana, K. Hasumi, and D. L. Mann, "Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity," Journal of Experimental & Clinical Cancer Research, vol. 29, article 134, 2010.
51. S. Coca, J. Perez-Piqueras, D. Martinez et al., "The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma," Cancer, vol. 79, no. 12, pp. 2320-2328, 1997.
52. F. R. Villegas, S. Coca, V. G. Villarrubia et al., "Prognostic significance of tumor infiltrating natural killer cells subsetCD57 in patients with squamous cell lung cancer," Lung Cancer, vol. 35, no. 1, pp. 23-28, 2002.
53. D. Rosso, M. P. Rigueiro, P. Kassab et al., "Correlation of natural killer cells with the prognosis of gastric adenocarcinoma," Arquivos Brasileiros de Cirurgia Digestiva, vol. 25, no. 2, pp. 114-117, 2012.
54. H. Saito, S. Takaya, T. Osaki, and M. Ikeguchi, "Increased apoptosis and elevated Fas expression in circulating natural killer cells in gastric cancer patients," Gastric Cancer, vol. 16, no. 4, pp. 473-479, 2013.
55. X.-T. Wu, J.-Q. Liu, X.-T. Lu et al., "The enhanced effect of lupeol on the destruction of gastric cancer cells by NK cells," International Immunopharmacology, vol. 16, no. 2, pp. 332-340, 2013.
56. J. Wang, K. A. Reiss, R. Khatri, E. Jaffee, and D. Laheru, "Immune therapy in GI malignancies: a review," Journal of Clinical Oncology, vol. 33, no. 16, pp. 1745-1753, 2015.
57. M. E. Dudley, J. R. Wunderlich, P. F. Robbins et al., "Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes," Science, vol. 298, no. 5594, pp. 850-854, 2002.
58. E. Y.Woo, C. S. Chu, T. J.Goletz et al., "Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer," Cancer Research, vol. 61, no. 12, pp. 4766-4772, 2001.
59. C. H. June, "Principles of adoptive T cell cancer therapy," The Journal of Clinical Investigation, vol. 117, no. 5, pp. 1204-1212, 2007.
60. A. Mackensen, N. Meidenbauer, S. Vogl, M. Laumer, J. Berger, and R. Andreesen, "Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma," Journal of ClinicalOncology, vol. 24, no. 31, pp. 5060-5069, 2006.
61. Y. J. Kim, J. Lim, J. S. Kang et al., "Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells," Archives of Pharmacal Research, vol. 33, no. 11, pp. 1789-1795, 2010.
62. D. Sangiolo, "Cytokine induced killer cells as promising immunotherapy for solid tumors," Journal of Cancer, vol. 2, no. 1, pp. 363-368, 2011.
63. T. Hoshino, N. Seki, M. Kikuchi et al., "Hla class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer," International Journal of Cancer, vol. 70, no. 6, pp. 631-638, 1997.
64. J. Jiang, N. Xu, C. Wu et al., "Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokineinduced killer cells," Anticancer Research, vol. 26, no. 3, pp. 2237-2242, 2006.
65. C. Wu, J. Jiang, L. Shi, and N. Xu, "Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer," Anticancer Research, vol. 28,no. 6, pp. 3997-4002, 2008.
66. X. Du, R. Jin, N. Ning et al., "In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model," Oncology Reports, vol. 28, no. 5, pp. 1743-1749, 2012.
67. M. E. Dudley, J. R. Wunderlich, T. E. Shelton, J. Even, and S. A. Rosenberg, "Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients," Journal of Immunotherapy, vol. 26, no. 4, pp. 332-342, 2003.
68. R. B. Alexander and S. A. Rosenberg, "Long-term survival of adoptively transferred tumor-infiltrating lymphocytes in mice," The Journal of Immunology, vol. 145, no. 5, pp. 1615-1620, 1990.
69. S. A. Rosenberg, J. R. Yannelli, J. C. Yang et al., "Treatment of patients with metastatic melanoma with autologous tumorinfiltrating lymphocytes and interleukin 2," Journal of the National Cancer Institute, vol. 86, no. 15, pp. 1159-1166, 1994.
70. M. Tomšová, B. Melichar, I. Sedláková, and I. Šteiner, "Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma," Gynecologic Oncology, vol. 108, no. 2, pp. 415-420, 2008.
71. J. Galon, A. Costes, F. Sanchez-Cabo et al., "Type, density, and location of immune cells within human colorectal tumors predict clinical outcome," Science, vol. 313, no. 5795, pp. 1960-1964, 2006.
72. A. Amedei, E. Niccolai, M. Benagiano et al., "Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENOspecific Tregs accumulate in tumor tissue and inhibitTh1/Th17 effector cell functions," Cancer Immunology, Immunotherapy, vol. 62, no. 7, pp. 1249-1260, 2013.
73. A. Amedei, E. Niccolai, C. D. Bella et al., "Characterization of tumor antigen peptide-specific T cells isolated from the neoplastic tissue of patients with gastric adenocarcinoma," Cancer Immunology, Immunotherapy, vol. 58, no. 11, pp. 1819-1830, 2009.
74. C. A. Ramos and G. Dotti, "Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy," Expert Opinion on BiologicalTherapy, vol. 11, no. 7, pp. 855-873, 2011.
75. D.M.Barrett,N. Singh,D.L.Porter, S. A. Grupp, andC.H. June, "Chimeric antigen receptor therapy for cancer," Annual Review of Medicine, vol. 65, pp. 333-347, 2014.
76. H. Singh, J. S. E. Moyes, M. H. Huls, and L. J. N. Cooper, "Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor," Cancer Gene Therapy, vol. 22, pp. 95-100, 2015.
77. M. H. Kershaw, J. A. Westwood, C. Y. Slaney, and P. K. Darcy, "Clinical application of genetically modified T cells in cancer therapy," Clinical&Translational Immunology, vol. 3, article e16, 2014.
78. O.Goldberger, I.Volovitz, A.Machlenkin, E.Vadai, E. Tzehoval, and L. Eisenbach, "Exuberated numbers of tumor-specific T cells result in tumor escape," Cancer Research, vol. 68, no. 9, pp. 3450-3457, 2008.
79. S. Kailayangiri, B. Altvater, J. Meltzer et al., "The ganglioside antigen G D2 is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting," British Journal of Cancer, vol. 106, no. 6, pp. 1123-1133, 2012.
80. D. Hollyman, J. Stefanski, M. Przybylowski et al., "Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy," Journal of Immunotherapy, vol. 32, no. 2, pp. 169-180, 2009.
81. R. J. Brentjens, I. Rivière, J. H. Park et al., "Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias," Blood, vol. 118, no. 18, pp. 4817-4828, 2011.
82. J. H. Pinthus, T. Waks, K. Kaufman-Francis et al., "Immunogene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes," Cancer Research, vol. 63, no. 10, pp. 2470-2476, 2003.
83. C. H. J. Lamers, S. Sleijfer, A. G. Vulto et al., "Treatment of metastatic renal cell carcinomawith autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience," Journal of Clinical Oncology, vol. 24, no. 13, pp. e20-e22, 2006.
84. A. A. Chekmasova, T. D. Rao, Y. Nikhamin et al., "Successful eradication of established peritoneal ovarian tumors in SCIDBeige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen," Clinical Cancer Research, vol. 16, no. 14, pp. 3594-3606, 2010.
85. A. M. Intlekofer and C. B. Thompson, "At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy," Journal of Leukocyte Biology, vol. 94, no. 1, pp. 25-39, 2013.
86. S. Mocellin, C. Benna, and P. Pilati, "Coinhibitory molecules in cancer biology and therapy," Cytokine and Growth Factor Reviews, vol. 24, no. 2, pp. 147-161, 2013.
87. L. Chen and D. B. Flies, "Molecular mechanisms of T cell costimulation and co-inhibition," Nature Reviews Immunology, vol. 13, no. 4, pp. 227-242, 2013.
88. A. Ito, S. Kondo, K. Tada, and S. Kitano, "Clinical development of immune checkpoint inhibitors," BioMed Research International, vol. 2015,Article ID 605478, 12 pages, 2015.
89. D. H. Wang, L. Guo, and X. H. Wu, "Checkpoint inhibitors in immunotherapy of ovarian cancer," Tumor Biology, vol. 36, no. 1, pp. 33-39, 2015.
90. C. E. Rudd, A. Taylor, and H. Schneider, "CD28 and CTLA-4 coreceptor expression and signal transduction," Immunological Reviews, vol. 229, no. 1, pp. 12-26, 2009.
91. E. Sharon,H. Streicher, P. Goncalves, and H. X. Chen, "Immune checkpoint inhibitors in clinical trials," Chinese Journal of Cancer, vol. 33, no. 9, pp. 434-444, 2014.
92. C. J. Nirschl and C. G. Drake, "Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy," Clinical Cancer Research, vol. 19, no. 18, pp. 4917-4924, 2013.
93. T. R. Simpson, F. Li, W. Montalvo-Ortiz et al., "Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma," Journal of Experimental Medicine, vol. 210, no. 9, pp. 1695-1710, 2013.
94. D. R. Leach, M. F. Krummel, and J. P. Allison, "Enhancement of antitumor immunity by CTLA-4 blockade," Science, vol. 271, no. 5256, pp. 1734-1736, 1996.
95. A. van Elsas, A. A. Hurwitz, and J. P. Allison, "Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/ macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation," The Journal of Experimental Medicine, vol. 190, no. 3, pp. 355-366, 1999.
96. S. A.Quezada, T. R. Simpson, K. S. Peggs et al., "Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts," The Journal of Experimental Medicine, vol. 207, no. 3, pp. 637-650, 2010.
97. C. Ralph, E. Elkord, D. J. Burt et al., "Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma," Clinical Cancer Research, vol. 16, no. 5, pp. 1662-1672, 2010.
98. D. Wilson, L. Hiller, and J. I. Geh, "Review of second-line chemotherapy for advanced gastric adenocarcinoma," Clinical Oncology, vol. 17, no. 2, pp. 81-90, 2005.
99. G. Goel and W. Sun, "Cancer immunotherapy in clinical practice - the past, present, and future," Chinese Journal of Cancer, vol. 33, no. 9, pp. 445-457, 2014.
100. R. S. Herbst, J.-C. Soria, M. Kowanetz et al., "Predictive correlates of response to the anti-PD-L1 antibodyMPDL3280A in cancer patients," Nature, vol. 515, no. 7528, pp. 563-567, 2014.
101. P. C. Tumeh, C. L. Harview, J. H. Yearley et al., "PD-1 blockade induces responses by inhibiting adaptive immune resistance," Nature, vol. 515, no. 7528, pp. 568-571, 2014.
102. K. Muro, Y. Bang, V. Shankaran et al., "LBA15: a phase 1B study of pembrolizumab (pembro; MK-3475) in patients (PTS) with advanced gastric cancer," Annals of Oncology, vol. 25, supplement 4, 2014.
103. E. Romano and P. Romero, "The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors," Journal for Immunotherapy of Cancer, vol. 3, article 15, 2015.
104. M. A. Curran,W.Montalvo, H. Yagita, and J. P. Allison, "PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors," Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 9, pp. 4275-4280, 2010.
105. J. Duraiswamy, K. M. Kaluza, G. J. Freeman, and G. Coukos, "Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors," Cancer Research, vol. 73, no. 12, pp. 3591-3603, 2013.
106. M. Noguchi, T. Sasada, and K. Itoh, "Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine," Cancer Immunology, Immunotherapy, vol. 62, no. 5, pp. 919-929, 2013.
107. P. Sharma and J. P. Allison, "The future of immune checkpoint therapy," Science, vol. 348, no. 6230, pp. 56-61, 2015.
108. D. S. Shin and A. Ribas, "The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?" Current Opinion in Immunology, vol. 33, pp. 23-35, 2015.
109. K. M. Mahoney, G. J. Freeman, and D. F. McDermott, "The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma," Clinical Therapeutics, vol. 37, no. 4, pp. 764-782, 2015.
110. Cancer Genome Atlas Research Network, "Comprehensive molecular characterization of gastric adenocarcinoma," Nature, vol. 513, no. 7517, pp. 202-209, 2014.
111. A. Covre, S. Coral, A. M. Di Giacomo, P. Taverna,M. Azab, and M.Maio, "Epigeneticsmeets immune checkpoints," Seminars in Oncology, vol. 42, no. 3, pp. 506-513, 2015.
112. W. Wang, W. Ji, H. Hu et al., "Survivin promoter-regulated oncolytic adenovirus with Hsp70 gene exerts effective antitumor efficacy in gastric cancer immunotherapy," Oncotarget, vol. 5, no. 1, pp. 150-160, 2014.